# Liver Function Assessment - Feasibility and Dosing Study

> **NCT02516319** · NA · TERMINATED · sponsor: **Cardiox Corporation** · enrollment: 57 (actual)

## Conditions studied

- Hepatic Failure

## Interventions

- **DRUG:** ICG Dye

## Key facts

- **NCT ID:** NCT02516319
- **Lead sponsor:** Cardiox Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-09
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 57 (ACTUAL)
- **Why stopped:** Business decision to discontinue product development.
- **Last updated:** 2016-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02516319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02516319, "Liver Function Assessment - Feasibility and Dosing Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02516319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*